Alembic Pharmaceuticals receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel

8 Aug 2022 , 11:04 AM

Alembic Pharmaceuticals (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Epiduo Forte Topical Gel, 0.3%/2.5%, of Galderma Laboratories, L.P; (Galderma). Adapalene and Benzoy Peroxide Topical Gel, 0.3%/2.5% is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5% has an estimated market size of US$211 million for twelve months ending Mar 2022 according to IQVIA. Alembic has received a cumulative total of 170 ANDA approvals (146 final approvals and 24 tentative approvals) from USFDA.Powered by Capital Market – Live News